Free Trial

Oncolytics Biotech (TSE:ONC) Stock Price Up 18.2% - Here's What Happened

Oncolytics Biotech logo with Medical background

Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s share price traded up 18.2% during mid-day trading on Tuesday . The company traded as high as C$1.69 and last traded at C$1.62. 747,191 shares changed hands during mid-day trading, an increase of 455% from the average session volume of 134,529 shares. The stock had previously closed at C$1.37.

Analysts Set New Price Targets

Separately, Jones Trading cut shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.

View Our Latest Report on Oncolytics Biotech

Oncolytics Biotech Price Performance

The company's 50-day moving average is C$0.81 and its two-hundred day moving average is C$0.94. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The firm has a market cap of C$116.38 million, a P/E ratio of -4.21 and a beta of 1.35.

About Oncolytics Biotech

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Featured Articles

Should You Invest $1,000 in Oncolytics Biotech Right Now?

Before you consider Oncolytics Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.

While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines